Drug intelligence / Profile preview

sevoflurane + neostigmine

Development stage: Unknown
Modality: Small Molecules
Administration: Inhalation, Intravenous

Overview

This combination represents the concurrent use of sevoflurane (an inhalational anesthetic) with neostigmine (a cholinesterase inhibitor). Studies show that sevoflurane significantly impacts neostigmine's ability to reverse neuromuscular blockade. Higher concentrations of sevoflurane and continued administration during reversal are associated with delayed recovery of neuromuscular function. Neostigmine can effectively reverse vecuronium-induced or rocuronium-induced neuromuscular blockade, but its efficacy is reduced when sevoflurane is continued during the reversal process.

Targets

Glycine receptorGABRR (GABA-A receptor subunit rho)Nicotinic Acetylcholine ReceptorAcetylcholinesterase

Beyond the preview

Go deeper on sevoflurane + neostigmine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sevoflurane + neostigmine.

Explore the full profile